These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34215993)

  • 1. Bisphosphonates, Bone and Joint Pain.
    Villatoro-Villar M; Kwoh CK
    Curr Osteoporos Rep; 2021 Aug; 19(4):417-428. PubMed ID: 34215993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review.
    Davis AJ; Smith TO; Hing CB; Sofat N
    PLoS One; 2013; 8(9):e72714. PubMed ID: 24023766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.
    Rossini M; Orsolini G; Viapiana O; Adami S; Gatti D
    Endocrine; 2015 Aug; 49(3):620-7. PubMed ID: 25649760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Bisphosphonates Alleviate Pain in Children? A Systematic Review.
    Celin MR; Simon JC; Krzak JJ; Fial AV; Kruger KM; Smith PA; Harris GF
    Curr Osteoporos Rep; 2020 Oct; 18(5):486-504. PubMed ID: 32960409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents.
    Herrero-Beaumont G; Roman-Blas JA
    Nat Rev Rheumatol; 2013 Aug; 9(8):448-50. PubMed ID: 23857129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient migratory osteoporosis: rapid response to pamidronate treatment.
    Carty S; Herdman G; Williams F; Srinivasan U
    J Clin Rheumatol; 2007 Jun; 13(3):138-9. PubMed ID: 17551379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis].
    Miyakoshi N
    Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
    Verron E; Bouler JM
    Drug Discov Today; 2014 Mar; 19(3):312-9. PubMed ID: 23974069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.
    Caffarelli C; Montagnani A; Nuti R; Gonnelli S
    Clin Interv Aging; 2017; 12():1819-1828. PubMed ID: 29133976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
    Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T
    Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bisphosphonates in treatment of transient osteoporosis.
    Kibbi L; Touma Z; Khoury N; Arayssi T
    Clin Rheumatol; 2008 Apr; 27(4):529-32. PubMed ID: 17938988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2011 Jul; 69(7):1253-7. PubMed ID: 21774367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis.
    Feng Z; Zeng S; Wang Y; Zheng Z; Chen Z
    PLoS One; 2013; 8(12):e80890. PubMed ID: 24324644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of anti-resorptive therapy for osteoporosis.
    Adler RA
    Endocrine; 2016 Feb; 51(2):222-4. PubMed ID: 26433739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment strategy of osteoporosis after the bisphosphonates discontinuation.].
    Soen S
    Clin Calcium; 2017; 27(2):273-280. PubMed ID: 28123130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.